Zhengye Biotechnology Holding Limited revenue by segment ZYBT
Annual
Quarterly
Zhengye Biotechnology Holding Limited splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Distribution Network at $8.8 million, 53% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
|---|---|---|
| Revenue |
17
|
26
|
| Distribution Network |
9
share 52.9%
|
—
|
| Direct Sales Channel |
7
share 44.6%
|
—
|
| Government Tender And Procurement |
0
share 2.5%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZYBT (Nasdaq)
- Incorporated in
- China
- Headquarters
- Jilin
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1975641
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.